Paper2864056
Celiprolol: pharmacokinetics and duration of pharmacodynamic activity.
Caruso FS and 5 others. Br J Clin Pract Suppl, 1985. Cited by 38 papers, by iCite.
Cite this record
ConductScience Library. Celiprolol: pharmacokinetics and duration of pharmacodynamic activity. Papers, record 2864056. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/2864056
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics6
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Adrenergic beta-Antagonists | Major topic |
| Propanolamines | Major topic |
| Celiprolol | |
| Humans | |
| Kinetics | |
| Time Factors |
Source PubMed
Cited by22
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 38 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 39064294 | Current Evidence and Future Perspectives in the Medical Management of Vascular Ehlers-Danlos Syndrome: Focus on Vascular Prevention. | J Clin Med | 2024 | https://conductscience.org/library/papers/39064294 | PubMed |
| 35245290 | Comparative therapeutic strategies for preventing aortic rupture in a mouse model of vascular Ehlers-Danlos syndrome. | PLoS Genet | 2022 | https://conductscience.org/library/papers/35245290 | PubMed |
| 34112223 | Extracorporeal treatment for poisoning to beta-adrenergic antagonists: systematic review and recommendations from the EXTRIP workgroup. | Crit Care | 2021 | https://conductscience.org/library/papers/34112223 | PubMed |
| 34009624 | Analysis of Non-linear Pharmacokinetics of P-Glycoprotein Substrates in a Microfluidic Device Using a Mathematical Model that Includes an Unstirred Water Layer (UWL) Compartment. | Pharm Res | 2021 | https://conductscience.org/library/papers/34009624 | PubMed |
| 31789518 | Urea Derivatives in Modern Drug Discovery and Medicinal Chemistry. | J Med Chem | 2020 | https://conductscience.org/library/papers/31789518 | PubMed |
| 31030372 | Predictive Value of Microdose Pharmacokinetics. | Clin Pharmacokinet | 2019 | https://conductscience.org/library/papers/31030372 | PubMed |
| 28742547 | Celiprolol: A Unique Selective Adrenoceptor Modulator. | Cardiol Rev | 2017 | https://conductscience.org/library/papers/28742547 | PubMed |
| 20135207 | Model analysis of the concentration-dependent permeability of P-gp substrates. | Pharm Res | 2010 | https://conductscience.org/library/papers/20135207 | PubMed |
| 8834196 | Celiprolol double-peak occurrence and gastric motility: nonlinear mixed effects modeling of bioavailability data obtained in dogs. | J Pharmacokinet Biopharm | 1995 | https://conductscience.org/library/papers/8834196 | PubMed |
| 8573993 | Celiprolol. An evaluation of its pharmacological properties and clinical efficacy in the management of hypertension and angina pectoris. | Drugs Aging | 1995 | https://conductscience.org/library/papers/8573993 | PubMed |
| 8058631 | The contribution of intestinal secretion to the dose-dependent absorption of celiprolol. | Pharm Res | 1994 | https://conductscience.org/library/papers/8058631 | PubMed |
| 7913813 | A risk-benefit assessment of celiprolol in the treatment of cardiovascular disease. | Drug Saf | 1994 | https://conductscience.org/library/papers/7913813 | PubMed |
| 7905337 | Transport of celiprolol across human intestinal epithelial (Caco-2) cells: mediation of secretion by multiple transporters including P-glycoprotein. | Br J Pharmacol | 1993 | https://conductscience.org/library/papers/7905337 | PubMed |
| 2968268 | Comparison of the antihypertensive effects of celiprolol and acebutolol. | Eur J Clin Pharmacol | 1988 | https://conductscience.org/library/papers/2968268 | PubMed |
| 2908720 | Hemodynamic effects of celiprolol at rest and during exercise; a comparison with enalapril. | Cardiovasc Drugs Ther | 1988 | https://conductscience.org/library/papers/2908720 | PubMed |
| 2899439 | Importance of ancillary properties of beta blockers in angina: a study of celiprolol and atenolol. | Br Heart J | 1988 | https://conductscience.org/library/papers/2899439 | PubMed |
| 2890513 | Celiprolol. A preliminary review of its pharmacodynamic and pharmacokinetic properties and its therapeutic use in hypertension and angina pectoris. | Drugs | 1987 | https://conductscience.org/library/papers/2890513 | PubMed |
| 2566321 | Comparison of the cardiovascular and pulmonary effects of oral celiprolol, propranolol and placebo in normal volunteers. | Br J Clin Pharmacol | 1989 | https://conductscience.org/library/papers/2566321 | PubMed |
| 2150174 | Effect of celiprolol on large and small arteries of the forearm circulation in hypertensive patients. | Cardiovasc Drugs Ther | 1990 | https://conductscience.org/library/papers/2150174 | PubMed |
| 1982763 | Comparative enantioselective pharmacokinetic studies of celiprolol in healthy volunteers and patients with impaired renal function. | Eur J Clin Pharmacol | 1990 | https://conductscience.org/library/papers/1982763 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/2864056
GET https://conductscience.org/api/papers/v1/2864056/cited_by?page=2